BACKGROUND: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. PURPOSE: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
BACKGROUND: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. PURPOSE: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Gregory A Wiseman; Ellen Kornmehl; Bryan Leigh; William D Erwin; Donald A Podoloff; Stewart Spies; Richard B Sparks; Michael G Stabin; Thomas Witzig; Christine A White Journal: J Nucl Med Date: 2003-03 Impact factor: 10.057
Authors: Thomas E Witzig; Christine A White; Leo I Gordon; Gregory A Wiseman; Christos Emmanouilides; James L Murray; John Lister; Pratik S Multani Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Gregory A Wiseman; Bryan Leigh; William D Erwin; Dominick Lamonica; Ellen Kornmehl; Stewart M Spies; Daniel H S Silverman; Thomas E Witzig; Richard B Sparks; Christine A White Journal: Cancer Date: 2002-02-15 Impact factor: 6.860
Authors: C Chiesa; F Botta; A Coliva; M Maccauro; L Devizzi; A Guidetti; C Carlo-Stella; E Seregni; M A Gianni; E Bombardieri Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-20 Impact factor: 9.236
Authors: Kristoff Muylle; Patrick Flamen; Danielle J Vugts; Thomas Guiot; Ghanem Ghanem; Nathalie Meuleman; Pierre Bourgeois; Bruno Vanderlinden; Guus A M S van Dongen; Hendrik Everaert; Mélanie Vaes; Dominique Bron Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-20 Impact factor: 9.236
Authors: Anne Kirstine Arveschoug; Anne Charlotte Bekker; Peter Iversen; Henrik Bluhme; Gerda Elisabeth Villadsen; Peter Frøhlich Staanum Journal: EJNMMI Res Date: 2020-06-23 Impact factor: 3.138